Table 2.
Clinicopathological features for patients after re-evaluation
| HGG (n = 25) | AT/RT (n = 8) | CNS NB-FOXR2 (n = 7) | ETMR (n = 6) | EPN (n = 6) | OTHER (n = 14) | |
|---|---|---|---|---|---|---|
| Age at diagnosis, median (years) | 12.7 | 2.6 | 5.3 | 2.8 | 5.9 | 3.3 |
| Gender | ||||||
| Male | 12 (48%) | 4 (50%) | 3 (43%) | 6 (100%) | 3 (50%) | 9 (64%) |
| Female | 13 (52%) | 4 (50%) | 4 (57%) | ¨ | 3 (50%) | 5 (36%) |
| Location of primary tumor | ||||||
| Hemisphere | 18 (72%) | 7 (88%) | 7 (100%) | 5 (83%) | 6 (100%) | 9 (64%) |
| Central/Midline | 7 (28%) | 1 (12%) | ¨ | 1 (17%) | ¨ | 2 (14%) |
| Details unknown | 3 (22%) | |||||
| Metastatic status | ||||||
| M0 | 24 (96%) | 7 (88%) | 6 (86%) | 6 (100%) | 6 (100%) | 13 (93%) |
| M1-3 | 1 (4%) | ¨ | 1 (14%) | ¨ | ¨ | 1 (7%) |
| Details unknown | 1 (12%) | |||||
| Tumor resection | ||||||
| GTR | 8 (32%) | 3 (38%) | 5 (71%) | 2 (33%) | 4 (67%) | 7 (50%) |
| Partial resection | 9 (36%) | 1 (12%) | 2 (29%) | 1 (17%) | 1 (17%) | 2 (14%) |
| Biopsy | 4 (16%) | |||||
| Details unknown | 4 (16%) | 4 (50%) | 3 (50%) | 1 (17%) | 5 (36%) | |
| Radiotherapy received | ||||||
| Yes | 19 (76%) | 2 (25%) | 7 (100%) | 1 (17%) | 5 (83%) | 7 (50%) |
| No | 6 (20%) | 6 (75%) | ¨ | 5 (83%) | 1 (17%) | 7 (50%) |
| Chemotherapy received | ||||||
| Yes | 21 (84%) | 8 (100%) | 7 (100%) | 5 (83%) | 6 (100%) | 12 (85%) |
| No | 3 (12%) | ¨ | ¨ | 1 (17%) | ¨ | 2 (15%) |
| High-dose chemotherapy with stemcell rescue | ¨ | 1 (12%) | 2 (29%) | 2 (33%) | ¨ | 2 (14%) |
| Details unknown | 1 (4%) | ¨ | ¨ | ¨ | ¨ | ¨ |
| Survival data | ||||||
| 5-year progression free survival | 17% ± 17% | 25% ± 37% | 100% | 17% ± 48% | 83% ± 21% | 36% ± 27% |
| 5-year overall survival | 20% ± 16% | 25% ± 27% | 100% | 33% ± 35% | 100% | 50% ± 26% |
HGG, High-grade glioma; AT/RT, atypical teratoid rhabdoid tumour; EPN, ependymoma